ArticleFrontiers in pain research (Lausanne, Switzerland)2025
Repetitive transcranial magnetic stimulation at low frequency for the treatment of fibromyalgia. Results from the first treatment cohort at the brainwave clinic.
Article in Frontiers in pain research (Lausanne, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the clinical effectiveness of low-frequency repetitive transcranial magnetic stimulation (rTMS) in treating fibromyalgia (FM) in a real-world setting. Methods: Eighteen adults diagnosed with FM received 20 sessions of low-frequency rTMS over the right dorsolateral prefrontal cortex (DLPFC). Pain and symptom burden were assessed using the Numerical Rating Scale (NRS), Fibromyalgia Impact Questionnaire (FIQ), Sheehan Disability Scale (SDS), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Outcomes were compared using paired Results: Statistically significant improvements were observed in NRS, FIQ, BDI, and BAI. A non-significant trend towards reduced disability (SDS) was observed. No serious adverse effects were reported. Conclusion: Low-frequency rTMS over the DLPFC shows promise as a safe and effective treatment for FM, improving pain, mood, and impact of FM symptoms, with a trend towards improving disability. Further research with larger cohorts is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.